JLK

Cheongju, South Korea All South Korea companies → — Founded 2014

Clinical AI Platform Imaging AI Specialist

Emergency Medicine Neurology Neurosurgery Oncology

Neurology AI Oncology AI Radiology & Imaging AI Triage & ER/ICU AI

Publicly Traded (KOSDAQ) — $31M

Claim this company

Products

Medihub Prostate

JLK

Oncology AI

MEDIHUB Prostate by JLK is an FDA-cleared AI solution for prostate cancer diagnosis, analyzing multiparametric MR images and PSA levels to assist radiologists and urologists in clinical interpretation.

Contact for pricing

JLK-SDH

JLK, Inc.

Neurology AI

JLK-SDH is an AI-powered subdural hemorrhage (SDH) detection tool developed by JLK Inc. It is designed to analyze CT scans for suspected SDH, providing rapid detection and notification to emergency physicians to aid in timely triage and decision-making.

Contact for pricing

JBS-LVO

JLK Inc.

Neurology AI

JBS-LVO by JLK Inc. is an FDA-cleared AI-powered radiological computer-aided triage and notification software designed for the rapid detection of suspected large vessel occlusions (LVOs) in acute stroke patients using CT angiography images.

See all 4 products →

About JLK

JLK Inc., formerly known as JLK Inspection Inc., is a South Korea-based healthcare AI company specializing in advanced medical solutions. The company develops and supplies AI-powered solutions that cover the entire stroke treatment cycle, including cerebral hemorrhage and cerebral infarction. Their comprehensive portfolio extends to neurological diseases such as dementia and brain aging, as well as various cancer types including prostate, breast, and lung cancer.

JLK’s flagship medical solution, ‘AIHuB,’ is designed to support the diagnosis of 37 diseases across 14 body regions, seamlessly integrating with existing imaging diagnosis systems. They offer full-cycle brain solutions that utilize diverse imaging modalities like CT, CTP, MRI, and MRA for accurate analysis. The company has secured multiple U.S. FDA 510(k) clearances for its AI-powered medical imaging platform, JLK-AILink, and various stroke diagnosis tools, aiming to enhance hospital efficiency and streamline clinical workflows. Additionally, JLK is involved in telemedicine services through its ‘MEDIHUB TELE’ platform and is developing AI solutions tailored for health check-up institutions.

Focus Areas

Stroke Dementia Cancer Brain aging Telemedicine Medical imaging analysis AI medical data management

Business Intelligence

Key Investors	KB Investment Co., Ltd, Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., NH Investment & Securities Co., Ltd.
Partnerships	Hallym University Sacred Heart Hospital, major university hospitals in Korea, Marubeni's Clairvo
Technology	AIHuB, MEDIHUB STROKE, MEDIHUB Dementia & Cancer Solutions, MEDIHUB TELE, Hello Data, Snappy (mobile app), deep learning, neural networks, DICOM standard, multi-modal medical imaging analysis
FDA Clearances	At least 6 cleared products (estimated)

What Physicians Need to Know

Stroke

JLK offers a comprehensive suite of AI-powered solutions for the entire stroke care continuum, encompassing cerebral hemorrhage, infarction, and aneurysm. Their solutions, such as JLK-LVO, JLK-CTP, JLK-PWI, JLK-DWI, JLK-FLAIR, JLK-ICH, and JLK-NCCT, analyze multi-modality images (CT, CTA, MRI, MRA) to shorten diagnosis and treatment workflows and improve patient prognosis.

Dementia & Brain Aging

JLK provides precision analysis solutions for dementia and brain aging. Their ATROSCAN solution utilizes MRI to analyze brain aging status, cortical area segmentation, and cortical thickness quantification, offering insights into the progression of brain aging compared to normal cohorts.

Cancer

The company develops precision cancer analysis solutions, including AI for breast cancer detection (JBD-01K), prostate cancer analysis (JPC-01K, Medihub Prostate), and lung abnormalities diagnosis (JLD-01K, JVIEWER-X, MEDIHUB CXR). They are also involved in R&D for AI cancer analysis based on digital pathology.

Telemedicine

JLK's MEDIHUB TELE platform facilitates easy access to telemedicine services, allowing users to upload medical data, receive AI analysis results via mobile, and consult with specialists. Their 'Hello Health' mobile platform supports personal healthcare management and non-face-to-face communication, with regulatory approval for international telemedicine services.

Medical Imaging Analysis

A core specialization, JLK's AI solutions perform multi-modality medical image analysis across CT, CTA, MRI, MRA, X-ray, and Mammography. Their JLK-AILink platform integrates imaging management and data analysis, providing precise image annotation, measurement, and manipulation.

AI Medical Data Management

JLK developed 'Hello Data,' an AI Medical Data Management Platform, to optimize the efficiency of high-priced medical data and ensure high accuracy for AI machine learning. 'Hello Data MEDI' is specifically designed for medical data.

Key Differentiators

JLK stands out with its full-cycle solutions, particularly in stroke care (11 types of solutions), and broad disease coverage (over 30 conditions across 14 body regions via AIHuB). They hold extensive global regulatory approvals (FDA, MFDS, PMDA, CE) and leverage proprietary AI, deep learning algorithms, and mobile integration for real-time diagnostics. They are also recognized as the first medical AI company listed on Korea's KOSDAQ.

Technology Stack

The core technology stack revolves around advanced AI and Machine Learning, utilizing artificial neural networks and deep learning for image analysis. They specialize in processing various medical imaging modalities (CT, MRI, X-ray). Their platforms incorporate robust data management systems and mobile development for accessibility, adhering to DICOM standards for seamless integration.

Physician Tip

For physicians, JLK's solutions offer faster and more accurate diagnoses, especially critical in acute conditions like stroke, by significantly shortening workflow times. The objective, quantitative AI analysis aids in precise treatment decisions and prognosis predictions across neurological and oncological conditions. Real-time access to AI-driven insights via mobile applications enhances usability in emergency scenarios. Furthermore, the seamless integration with existing hospital systems (PACS, DICOM compliant) minimizes disruption and improves overall workflow efficiency, potentially addressing specialist shortages by providing robust diagnostic support.

JLK's AI-powered medical imaging platforms, such as JLK-AILink and AIHuB, are designed for seamless integration with existing hospital systems. They adhere to the DICOM standard, ensuring high security and stability, and can interlock with Picture Archiving and Communication Systems (PACS) for efficient data access and review. This allows for easy incorporation of AI-driven insights into current clinical workflows.

At a glance

Founded 2014

HQ Cheongju, South Korea · South Korea

Team size 83

CEO Kim Dong-min

Funding Publicly Traded (KOSDAQ) — $31M

FDA clearances At least 6 (estimated)

Products 4

Products by JLK

4 products in the directory

Medihub Prostate

JLK

Oncology AI

Contact for pricing

JLK-SDH

JLK, Inc.

Neurology AI

Contact for pricing

JBS-LVO

JLK Inc.

Neurology AI

JLK-ICH

JLK, Inc.

Neurology AI

JLK-ICH is an FDA-cleared AI-powered radiological computer-assisted triage and notification software that rapidly detects suspected intracranial hemorrhage from non-contrast CT images, providing critical alerts to specialists.

Contact for pricing

Reviews & Opinions

No web reviews on file yet for JLK. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about JLK.

Loading videos...

Videos load interactively. If none appear, search YouTube for JLK →

View all on YouTube

Press & Coverage

KBR

JLK wins US patent for brain lesion analysis AI technology

JLK, a medical AI company, secured a U.S. patent for its AI technology that detects abnormal lesions in cerebrovascular areas to reduce stroke risk. This patent strengthens JLK's foundation for entering the U.S. market with its full-cycle stroke analysis solution.

2024-01

KBR

JLK secures FDA clearance for AI-powered medical imaging platform

JLK received U.S. FDA 510(k) clearance for JLK-AILink, its AI-powered medical imaging platform, marking its sixth FDA approval. The platform integrates medical imaging management and data analysis to enhance hospital efficiency and facilitate U.S. market adoption.

2025-02

GlobeNewswire

JLK Unveils Its AI-Powered Imaging Diagnosis Solutions for Stroke

JLK announced its ambition to dominate the U.S. healthcare market with its AI-powered advanced imaging diagnosis solutions for stroke, preparing FDA applications and aiming for insurance reimbursements by 2024. The company boasts 11 stroke solutions compatible with various medical imaging devices.

2023-08

Businesskorea

JLK's AI Stroke Solution Receives FDA Approval

JLK's AI stroke solution, JLK-LVO, received 510(k) clearance from the U.S. FDA, a significant milestone for the company's stroke solutions. This approval is expected to expedite regulatory processes for other JLK products and facilitate entry into the U.S. insurance reimbursement market.

2024-10

KED Global

JLK gets OK from FDA for ICH diagnosis solution

JLK Inc. received 501K approval from the US FDA for its AI-based intracerebral hemorrhage (ICH) diagnosis solution, JLK-ICH. This solution analyzes CT images to detect brain hemorrhage and will work with existing JLK products to address the entire stroke cycle.

2025-01

KBR

JLK gains FDA 510(k) clearance for NCCT-based AI stroke detection tool

JLK's non-contrast CT (NCCT)-based stroke analysis solution, JLK-NCCT, received FDA 510(k) clearance, recognizing its clinical value in rapid identification and prioritization of suspected stroke patients. This is significant for the initial stage of stroke care.

2026-03

KBR

JLK to supply healthcare AI solutions to Indonesia's largest hospital

JLK signed an agreement to supply medical AI software, including brain hemorrhage and aneurysm detection solutions, to Indonesia's largest hospital chain, Siloam hospitals. This partnership aims to improve public healthcare services and create a digital healthcare ecosystem in Indonesia.

2024-04

JLK, a medical artificial intelligence (AI) company, announced on the 24th that it has published the second verification paper of the AI-based large vascular occlusion detection solution (JLK-LVO) in the prestigious international journal 'JNIS' (Journal of Neurointerventional Surgery) related to stroke procedures.

JLK published a second verification paper for its AI-based large vascular occlusion detection solution (JLK-LVO) in the Journal of Neurointerventional Surgery (JNIS). The study, involving multicenter stroke specialists, demonstrated high sensitivity and specificity for JLK-LVO in detecting macrovascular occlusion.

2024-09

Frequently Asked Questions

What specific AI solutions does JLK offer for stroke, dementia, cancer, and brain aging, and how do they integrate with existing medical imaging workflows?

JLK provides a comprehensive suite of AI solutions, including 'MEDIHUB STROKE' for hemorrhage, infarction, and aneurysm analysis across CT, CTP, MRI, and MRA modalities, aiming to shorten diagnosis and treatment times. For dementia and brain aging, products like ATROSCAN and JAD-02K analyze MRI images to assess atrophy and cortical thickness, while cancer solutions cover various types using MRI, digital pathology, endoscopy, X-ray, and mammography. Their platforms, such as JLK-AILink, are designed to integrate seamlessly with existing systems by adhering to DICOM standards, enabling consolidated analysis and real-time mobile notifications.

What regulatory compliance and certifications does JLK hold for its AI medical devices, particularly in major markets like the U.S. and Europe?

JLK holds numerous global medical AI licenses, including approvals from the MFDS (Korea), FDA (U.S.), PMDA (Japan), and CE (Europe), demonstrating broad regulatory acceptance. They have secured multiple FDA 510(k) clearances for various stroke solutions and their integrated medical imaging platform, JLK-AILink. These certifications ensure their products meet stringent safety and effectiveness standards for clinical use in key international markets.

Can you explain JLK's pricing model for its AI solutions and the typical support structure provided to healthcare institutions?

JLK is transitioning towards a subscription-based package model for its AI solutions, particularly noted in markets like Japan, which aims for higher profitability and faster monetization compared to single-product sales. While specific pricing details vary by product and region, one stroke solution, JBS-01K, has a per-use cost in South Korea and is approved for non-reimbursed use. Support is facilitated through their integrated platforms, offering features like mobile notifications with real-time updates and adherence to DICOM standards for secure and stable operation.

How does JLK address AI medical data management and security concerns, especially when integrating with hospital systems or facilitating telemedicine?

JLK addresses AI medical data management through its 'Hello Data' platform, which includes 'Hello Data MEDI' specifically optimized for medical data and AI machine learning. For security, their JLK-AILink platform adheres to the DICOM standard, ensuring high security and stability for image management and analysis. Their telemedicine solution, MEDIHUB TELE, allows secure uploading and management of medical data, with AI analysis results accessible via mobile.

What is JLK's current market position, and what are its strategic partnerships and long-term stability outlook in the competitive medical AI landscape?

JLK is a listed company on the Korean KOSDAQ market and is actively expanding its global footprint, aiming for a significant market share in the US stroke care market against competitors like RapidAI and Viz.ai. They have established strategic partnerships, including an exclusive sales contract with Japan's largest remote diagnostic company, DoctorNet, and maintain local subsidiaries in the US and Japan. Despite reporting negative net income and being considered overvalued by some financial analyses, JLK has ambitious growth targets and a consistent track record of obtaining regulatory approvals, indicating a focus on long-term market penetration and product innovation.

Comparisons

NeuroQuant vs JLK-SDH

Related Companies

Suggest an Edit →